Cepheid (FRA:XEP) Debt-to-Equity : 0.76 (As of Sep. 2016)

View and export this data going back to . Start your Free Trial

What is Cepheid Debt-to-Equity?

Cepheid's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2016 was €0.0 Mil. Cepheid's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2016 was €258.2 Mil. Cepheid's Total Stockholders Equity for the quarter that ended in Sep. 2016 was €339.2 Mil. Cepheid's debt to equity for the quarter that ended in Sep. 2016 was 0.76.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cepheid's Debt-to-Equity or its related term are showing as below:

FRA:XEP's Debt-to-Equity is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 0.22
* Ranked among companies with meaningful Debt-to-Equity only.

Cepheid Debt-to-Equity Historical Data

The historical data trend for Cepheid's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cepheid Debt-to-Equity Chart

Cepheid Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.79

0.76

Cepheid Quarterly Data
	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Debt-to-Equity	Get a 7-Day Free Trial															0.78	0.76	0.75	0.76	0.76

Competitive Comparison of Cepheid's Debt-to-Equity

For the Diagnostics & Research subindustry, Cepheid's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cepheid's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cepheid's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cepheid's Debt-to-Equity falls into.

Cepheid Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cepheid's Debt to Equity Ratio for the fiscal year that ended in Dec. 2015 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	258.534)	/	339.644
	=	0.76

Cepheid's Debt to Equity Ratio for the quarter that ended in Sep. 2016 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	258.174)	/	339.156
	=	0.76

Cepheid (FRA:XEP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cepheid Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cepheid's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cepheid (FRA:XEP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cepheid (FRA:XEP) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cepheid.com

Cepheid was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's product portfolio consists of tests, reagents and systems for the clinical and non-clinical markets. The Company's two systems are the GeneXpert and SmartCycler. The GeneXpert system, offers services in the clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. Company faces competition from a number of companies that offer products to its target markets. Company has patents covering technologies of its own and has licensed technologies from others. In addition to patents, it rely on a combination of trade secrets, copyright and trademark laws, nondisclosure agreements, licenses and other contractual provisions and technical measures to maintain and develop its competitive position with respect to intellectual property. In the Clinical market, its products are regulated as medical device products by the FDA and comparable agencies in other countries. For the Non-Clinical market, all of its products are being produced under ISO 13485 and Quality System Regulations.

Cepheid (FRA:XEP) Headlines

No Headlines